 | Up a level |
Akinloye, Abdulafeez, Oyedeji, Timothy, Eniayewu, Oluwasegun, Adeagbo, Babatunde, Bolaji, Oluseye, Rannard, Steve, Owen, Andrew and Olagunju, Adeniyi 
ORCID: 0000-0002-6588-5749
(2023)
Atazanavir/ritonavir increased tizoxanide exposure from oral nitazoxanide through pharmacokinetic interaction in healthy volunteers.
[Preprint]
Olagunju, Adeniyi ORCID: 0000-0002-6588-5749, Fowotade, Adeola, Olagunoye, Ajibola, Ojo, Temitope Olumuyiwa, Adefuye, Bolanle Olufunlola, Fagbamigbe, Adeniyi Francis, Adebiyi, Akindele Olupelumi, Olagunju, Omobolanle Ibitayo, Ladipo, Olabode Taiwo, Akinloye, Abdulafeez et al (show 6 more authors)
(2021)
Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
Trials, 22 (1).
3-.
Shenkoya, Babajide, Atoyebi, Shakir ORCID: 0000-0002-1393-3753, Eniayewu, Ibrahim, Akinloye, Abdulafeez and Olagunju, Adeniyi ORCID: 0000-0002-6588-5749
(2021)
Mechanistic Modeling of Maternal Lymphoid and Fetal Plasma Antiretroviral Exposure During the Third Trimester.
FRONTIERS IN PEDIATRICS, 9.
734122-.
Akinloye, Abdulafeez, Eniayewu, Oluwasegun, Adeagbo, Babatunde, Bolaji, Oluseye and Olagunju, Adeniyi ORCID: 0000-0002-6588-5749
(2022)
Validation and Clinical Application of a Liquid Chromatography-Ultraviolet Detection Method to Quantify Dolutegravir in Dried Blood Spots.
THERAPEUTIC DRUG MONITORING, 44 (3).
pp. 430-437.
Fowotade, Adeola, Bamidele, Folasade, Egbetola, Boluwatife, Fagbamigbe, Adeniyi F, Adeagbo, Babatunde A, Adefuye, Bolanle O, Olagunoye, Ajibola, Ojo, Temitope O, Adebiyi, Akindele O, Olagunju, Omobolanle I et al (show 8 more authors)
(2022)
A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19.
FRONTIERS IN MEDICINE, 9.
956123-.